

9 August 2023

## Xprecia Prime tender win in Italy

---

Universal Biosensors, Inc. (ASX: UBI) advises it has won its first major tender to supply Xprecia Prime in Italy.

The tender is for an initial period of two years commencing in Q423 and includes the purchase of more than a hundred Xprecia Prime devices and 130,000 strips pa.

Mr John Sharman, CEO of UBI said; "We are delighted to have won our first major tender in a large European market. Xprecia Prime is the flagship of our coagulation portfolio and this tender win follows our distribution partnership with EBOS group in Australia which we announced last month. Together these are meaningful contracts which will contribute to sales growth of Xprecia products globally."

For further information please refer to the XPRECIA website (<https://www.universalbiosensors.com/products/xprecia/>).

**End**

***Announcement authorised by the Board of Directors of Universal Biosensors, Inc.***

For further information contact:

John Sharman  
Chief Executive Officer  
+61 (0) 414 440 680

**About Universal Biosensors**

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), wine, food, and agriculture. UBI's ambition is to build a multi product stable of biosensors in large markets which generate ongoing revenue streams. For additional information regarding Universal Biosensors, Inc., refer to: <http://www.universalbiosensors.com>.

**Forward-Looking Statements**

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.